Dynamic within-host cefiderocol heteroresistance caused by blaSHV-12 amplification in pandrug-resistant and hypervirulent Klebsiella pneumoniae sequence type 11

被引:10
作者
Liu, Chao [1 ,2 ]
Yi, Juan [3 ]
Lu, Ming [1 ,2 ]
Yang, Ping [3 ]
Du, Chunjing [2 ,4 ]
Jiang, Fan [4 ]
Du, Pengcheng [5 ]
Shen, Ning [1 ,2 ,3 ,4 ,6 ]
机构
[1] Peking Univ Third Hosp, Dept Infect Dis, Beijing, Peoples R China
[2] Peking Univ Third Hosp, Ctr Infect Dis, Beijing, Peoples R China
[3] Peking Univ, Inst Med Technol, Hlth Sci Ctr, Beijing, Peoples R China
[4] Peking Univ Third Hosp, Dept Pulm & Crit Care Med, Beijing, Peoples R China
[5] Qitan Technol Ltd, Chengdu, Peoples R China
[6] Peking Univ Third Hosp, Dept Infect Dis, Dept Resp & Crit Care Med, Beijing, Peoples R China
基金
中国国家自然科学基金;
关键词
Hypervirulent Klebsiella pneumoniae; Cefiderocol resistance; bla SHV-12; ST11; Heteroresistance;
D O I
10.1016/j.drup.2023.101038
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims: Although cefiderocol (FDC) is not prescribed in China, FDC-resistant pandrug-resistant hypervirulent Klebsiella pneumoniae (PDR-hvKp) is emerging. In this study, we performed FDC susceptibility testing of clinical Kp isolates to explore the prevalence of FDC-resistant isolates and the mechanism of FDC-resistance. Methods: We retrospectively selected 151 carbapenem-resistant Kp isolates to assess FDC susceptibility. Seven isolates harboring blaSHV-12 from two patients were enrolled for whole-genome sequencing. The antimicrobial resistance, virulence, blaSHV-12 expression, and fitness costs in different media were examined. The amplification of blaSHV-12 was further investigated by qPCR and long-read sequencing. Results: The 151 isolates showed a low MIC50/MIC90 (1/4 mg/L) of FDC. The seven isolates were ST11 PDR-hvKp, and two represented FDC-resistance (MIC=32 mg/L). The IncR/IncFII plasmids of two FDC-resistant isolates harbored 6 and 15 copies of blaSHV-12, whereas four FDC-susceptible isolates carried one copy and one harbored three copies. These blaSHV-12 genes concatenated together and were located within the same 7.3 kb fragment flanked by IS26, which contributed to the increased expression and FDC resistance without fitness costs. The amplification of blaSHV-12 and FDC resistance could be induced by FDC in vitro and reversed during continuous passage. Conclusions: The amplification of blaSHV-12 and the consequent dynamic within-host heteroresistance are important concerns for the rational application of antibiotics. Long-read sequencing might be a superior way to detect resistance gene amplification rapidly and accurately.
引用
收藏
页数:9
相关论文
共 31 条
[1]   Mechanisms and clinical relevance of bacterial heteroresistance [J].
Andersson, Dan, I ;
Nicoloff, Herve ;
Hjort, Karin .
NATURE REVIEWS MICROBIOLOGY, 2019, 17 (08) :479-496
[2]   Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial [J].
Bassetti, Matteo ;
Echols, Roger ;
Matsunaga, Yuko ;
Ariyasu, Mari ;
Doi, Yohei ;
Ferrer, Ricard ;
Lodise, Thomas P. ;
Naas, Thierry ;
Niki, Yoshihito ;
Paterson, David L. ;
Portsmouth, Simon ;
Torre-Cisneros, Julian ;
Toyoizumi, Kiichiro ;
Wunderink, Richard G. ;
Nagata, Tsutae D. .
LANCET INFECTIOUS DISEASES, 2021, 21 (02) :226-240
[3]   In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection [J].
Candel, Francisco Javier ;
Henriksen, Anne Santerre ;
Longshaw, Christopher ;
Yamano, Yoshinori ;
Oliver, Antonio .
CLINICAL MICROBIOLOGY AND INFECTION, 2022, 28 (03) :447.e1-447.e6
[4]  
Choby JE, 2021, LANCET INFECT DIS, V21, P597, DOI 10.1016/S1473-3099(21)00194-8
[5]   Increased blaKPC Copy Number and OmpK35 and OmpK36 Porins Disruption Mediated Resistance to Imipenem/Relebactam and Meropenem/Vaborbactam in a KPC-Producing Klebsiella pneumoniae Clinical Isolate [J].
Gaibani, Paolo ;
Bianco, Gabriele ;
Amadesi, Stefano ;
Boattini, Matteo ;
Ambretti, Simone ;
Costa, Cristina .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2022, 66 (05)
[6]  
Gu DX, 2018, LANCET INFECT DIS, V18, P37, DOI [10.1016/S1473-3099(17)30489-9, 10.1016/s1473-3099(17)30489-9]
[7]   Cross-resistance to cefiderocol and ceftazidime-avibactam in KPC β-lactamase mutants and the inoculum effect [J].
Hobson, Claire Amaris ;
Cointe, Aurelie ;
Jacquier, Herve ;
Choudhury, Alaksh ;
Magnan, Melanie ;
Courroux, Celine ;
Tenaillon, Olivier ;
Bonacorsi, Stephane ;
Birgy, Andre .
CLINICAL MICROBIOLOGY AND INFECTION, 2021, 27 (08) :1172.e7-1172.e10
[8]   Piperacillin/tazobactam resistance in a clinical isolate of Escherichia coli due to IS26-mediated amplification of blaTEM-1B [J].
Hubbard, Alasdair T. M. ;
Mason, Jenifer ;
Roberts, Paul ;
Parry, Christopher M. ;
Corless, Caroline ;
van Aartsen, Jon ;
Howard, Alex ;
Bulgasim, Issra ;
Fraser, Alice J. ;
Adams, Emily R. ;
Roberts, Adam P. ;
Edwards, Thomas .
NATURE COMMUNICATIONS, 2020, 11 (01)
[9]   Localized pmrB hypermutation drives the evolution of colistin heteroresistance [J].
Kapel, Natalia ;
Caballero, Julio Diaz ;
MacLean, R. Craig .
CELL REPORTS, 2022, 39 (10)
[10]   In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study) [J].
Kazmierczak, Krystyna M. ;
Tsuji, Masakatsu ;
Wise, Mark G. ;
Hackel, Meredith ;
Yamano, Yoshinori ;
Echols, Roger ;
Sahm, Daniel F. .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2019, 53 (02) :177-184